GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmsynthez PJSC (MIC:LIFE) » Definitions » EBIT

Pharmsynthez PJSC (MIC:LIFE) EBIT : ₽-264.6 Mil (TTM As of Jun. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Pharmsynthez PJSC EBIT?

Pharmsynthez PJSC's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2023 was ₽-122.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was ₽-264.6 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pharmsynthez PJSC's annualized ROC % for the quarter that ended in Jun. 2023 was -6.63%. Pharmsynthez PJSC's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -71.66%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pharmsynthez PJSC's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -14.16%.


Pharmsynthez PJSC EBIT Historical Data

The historical data trend for Pharmsynthez PJSC's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmsynthez PJSC EBIT Chart

Pharmsynthez PJSC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.61 -2,019.48 -497.66 -697.03 -167.39

Pharmsynthez PJSC Semi-Annual Data
Dec11 Jun13 Dec13 Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -253.72 -443.31 -25.61 -141.78 -122.81

Competitive Comparison of Pharmsynthez PJSC's EBIT

For the Biotechnology subindustry, Pharmsynthez PJSC's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmsynthez PJSC's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmsynthez PJSC's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pharmsynthez PJSC's EV-to-EBIT falls into.



Pharmsynthez PJSC EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₽-264.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmsynthez PJSC  (MIC:LIFE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pharmsynthez PJSC's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

ROC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-112.984 * ( 1 - -15.4% )/( (2061.213 + 1872.409)/ 2 )
=-130.383536/1966.811
=-6.63 %

where

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1337.921 - 253.656 - ( 9.173 - max(0, 1175.05 - 198.102+9.173))
=2061.213

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1715.003 - 317.636 - ( 257.062 - max(0, 1037.882 - 562.84+257.062))
=1872.409

Note: The Operating Income data used here is two times the semi-annual (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Pharmsynthez PJSC's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Jun. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-245.614/( ( (344.578 + max(-288.014, 0)) + (340.894 + max(-17.136, 0)) )/ 2 )
=-245.614/( ( 344.578 + 340.894 )/ 2 )
=-245.614/342.736
=-71.66 %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(72.027 + 41.954 + 69.423) - (253.656 + 0 + 217.762)
=-288.014

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(214.849 + 85.061 + 0.59000000000003) - (317.636 + 0 + 0)
=-17.136

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pharmsynthez PJSC's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2023 )
=-264.589/1868.356
=-14.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmsynthez PJSC EBIT Related Terms

Thank you for viewing the detailed overview of Pharmsynthez PJSC's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmsynthez PJSC (MIC:LIFE) Business Description

Traded in Other Exchanges
N/A
Address
150 Engelsa Prospect, St. Petersburg, RUS, 194358
Pharmsynthez PJSC is a pharmaceutical company developing new medications, technologies of drugs for organ-specific delivery and innovative methods of manufacture for pharmaceutical ingredients. The company is engaged in the research and development, production and sales of officinal medicines (original OM) and active pharmaceutical ingredients (API).

Pharmsynthez PJSC (MIC:LIFE) Headlines

No Headlines